KPV (Lys-Pro-Val): Evidence Before Hype
KPV is a naturally occurring tripeptide corresponding to the C-terminal Lys-Pro-Val sequence of α-melanocyte-stimulating hormone (α-MSH). It has attracted research interest for its anti-inflammatory and immunomodulatory activity, particularly in gastrointestinal and inflammatory models.
The Founder’s Institute of Medicine & Education KPV Peptide Intelligence Monograph examines the evidence behind those claims — and separates promising preclinical findings from what has actually been demonstrated in humans.
Inside the monograph:
• Compound identity and biological origin
• Anti-inflammatory mechanisms and signaling
• Gastrointestinal and inflammatory bowel disease research
• PepT1 intestinal transport research
• Wound-healing and dermatologic claims
• Antimicrobial research
• Human evidence and its limitations
• Safety and toxicology uncertainties
• FDA and 2026 regulatory review
• Claim-by-claim FIPES evidence assessment
• Fully referenced scientific literature
Institute Bottom Line: KPV has a compelling preclinical anti-inflammatory and gastrointestinal research story, but human therapeutic efficacy and safety have not been established.
Version 1.0 | Evidence cutoff: August 25, 2026
Educational scientific evidence review. Not medical advice, a treatment protocol, prescription, or promotional claim.
This publication is provided solely for educational and informational purposes. It does not constitute medical advice, diagnosis, prescribing guidance, or a recommendation for individual treatment. It is not intended to replace evaluation, consultation, or treatment by a qualified healthcare professional. Treatment decisions must be based on the individual patient's circumstances and made in consultation with an appropriately licesnsed healthcare professional.